GO:0008265 molybdenum cofactor sulfurtransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0008265 describes the catalytic activity that transfers a sulfur atom onto the molybdenum cofactor (Mo-molybdopterin), converting it into its active thio-Mo-molybdopterin form.
• The reaction consumes L-cysteine and a reducing agent (AH2) and releases L-alanine, water, and the sulfurylated cofactor.
• In humans, the sulfurtransferase function is carried out by the MOCOS protein (molybdenum cofactor sulfurase), which acts downstream of MOCS1, MOCS2, and GPHN in the cofactor biosynthesis pathway.
• Loss of this activity causes molybdenum cofactor deficiency, a severe metabolic disorder with neonatal seizures, brain atrophy, and early death.
• MOCS2 variants, including a prevalent Roma founder allele, can produce mild or atypical forms of cofactor deficiency.
• Studying GO:0008265 requires combining genetic models (knockout, point mutation, knock-in) with biochemical assays for sulfite oxidase and xanthine dehydrogenase activity.
Description
Molybdenum cofactor sulfurtransferase activity (GO:0008265) is the enzymatic function that installs a sulfur atom on the molybdenum cofactor (Mo-molybdopterin), converting it into the catalytically active thio-Mo-molybdopterin form required by molybdoenzymes such as sulfite oxidase, xanthine dehydrogenase, and aldehyde oxidase. Without this sulfur transfer step, the cofactor remains in a desulfo state and the downstream enzymes cannot perform their redox chemistry. The reaction is formally described as AH2 + L-cysteine + Mo-molybdopterin = A + H2O + L-alanine + thio-Mo-molybdopterin, meaning that a reducing agent and the amino acid L-cysteine provide the sulfur and electrons needed for the modification. This activity is of broad interest because it sits at the intersection of sulfur metabolism, molybdenum homeostasis, and human inherited disease. In humans, mutations in the genes that build and sulfurylate the cofactor cause molybdenum cofactor deficiency, a rare but devastating condition characterized by intractable seizures, developmental regression, and early death. The sulfurtransferase step is particularly important because it is the final activation event: even if the cofactor backbone is made correctly, a failure to sulfurylate it leaves molybdoenzymes inactive. For researchers, GO:0008265 provides a precise functional annotation that can be used to interpret genome-scale data, design CRISPR models, and connect genotype to biochemical phenotype. The term is also relevant to bacterial systems, where FeS cluster assembly and molybdenum cofactor maturation are tightly linked, and to veterinary medicine, where hereditary xanthinuria in goats has been linked to defects in the same pathway. Understanding the sulfurtransferase mechanism therefore has implications for rare disease diagnosis, metabolic engineering, and comparative biology.
molybdenum cofactor sulfurtransferase activity At A Glance
| GO ID | GO:0008265 |
|---|---|
| GO term | molybdenum cofactor sulfurtransferase activity |
| Ontology | molecular_function |
| Synonym | molybdopterin cofactor sulfurase activity; molybdopterin synthase sulfurylase activity; Mo-molybdopterin cofactor sulfurase activity; Mo-molybdopterin cofactor sulphurase activity |
| Major function | Sulfurylation of Mo-molybdopterin to form active thio-Mo-molybdopterin |
| Reaction | AH2 + L-cysteine + Mo-molybdopterin = A + H2O + L-alanine + thio-Mo-molybdopterin |
| Substrates | L-cysteine, Mo-molybdopterin, reducing agent (AH2) |
| Products | L-alanine, H2O, thio-Mo-molybdopterin |
| Related pathway | Molybdenum cofactor biosynthesis and maturation |
What Is GO:0008265?
In simple terms, GO:0008265 is the activity that puts a sulfur atom onto the molybdenum cofactor so that molybdoenzymes can work. More formally, it catalyzes the reaction AH2 + L-cysteine + Mo-molybdopterin = A + H2O + L-alanine + thio-Mo-molybdopterin, using L-cysteine as the sulfur donor and a reducing agent (AH2) to drive the transfer. The product, thio-Mo-molybdopterin, is the active form of the cofactor that is inserted into enzymes such as sulfite oxidase and xanthine dehydrogenase.
Why Is molybdenum cofactor sulfurtransferase activity Important in Cell Biology?
GO:0008265 is important because it represents the final activation step of the molybdenum cofactor, a prosthetic group required by a small but essential set of enzymes that control sulfur, purine, and aldehyde metabolism. When this activity is lost, molybdoenzymes remain inactive even if the cofactor backbone is present, leading to the accumulation of toxic metabolites such as sulfite and xanthine. This makes the sulfurtransferase step a critical node for understanding molybdenum cofactor deficiency, a severe inherited metabolic disorder, and for interpreting genetic variants of uncertain significance in the cofactor pathway.
• Defines the final activation step of the molybdenum cofactor, without which sulfite oxidase and xanthine dehydrogenase are non-functional.
• Loss-of-function mutations in the human sulfurtransferase gene MOCOS cause molybdenum cofactor deficiency, a neonatal-onset metabolic disease.
• MOCS2 variants, including a Roma founder mutation, can cause mild or atypical cofactor deficiency, expanding the phenotypic spectrum.
• Provides a biochemical explanation for hereditary xanthinuria, as seen in goats with defects in the same pathway.
• Links sulfur amino acid metabolism to molybdenum homeostasis and FeS cluster biology in bacteria.
• Serves as a functional annotation for genome-wide studies of molybdoenzyme maturation.
• Enables the design of CRISPR models to test variant pathogenicity in the cofactor pathway.
• Supports diagnostic strategies for rare metabolic disorders with seizure and encephalopathy phenotypes.
• Relevant to metabolic engineering of molybdoenzymes in biotechnology.
• Provides a target for therapeutic approaches aimed at restoring cofactor sulfurylation.
Molecular Mechanism of molybdenum cofactor sulfurtransferase activity
Substrate recognition and sulfur donor
In simple terms: The enzyme picks up L-cysteine and uses it as the sulfur source.
The sulfurtransferase reaction requires L-cysteine as the sulfur donor and a reducing agent (AH2) to maintain the cofactor in a reactive state. The enzyme binds Mo-molybdopterin and positions the cysteine so that its sulfur can be transferred to the molybdenum center, releasing L-alanine and water as byproducts. This step is distinct from the earlier steps of cofactor biosynthesis, which build the molybdopterin backbone but do not sulfurylate it.
Catalytic transfer to molybdenum
In simple terms: The sulfur is attached to the molybdenum atom, turning the cofactor on.
During catalysis, the sulfur atom from L-cysteine is transferred to the molybdenum atom of Mo-molybdopterin, forming thio-Mo-molybdopterin. This modification is essential for the cofactor to support redox reactions in molybdoenzymes such as sulfite oxidase and xanthine dehydrogenase. The reaction is formally an oxidative sulfur transfer, with AH2 serving as the electron donor.
Cofactor and metal requirements
In simple terms: The enzyme needs the cofactor itself and may depend on iron-sulfur cluster assembly.
The sulfurtransferase acts on Mo-molybdopterin, which contains a molybdenum atom coordinated by the pterin scaffold. In bacteria, maturation of molybdoenzymes is closely tied to FeS cluster biosynthesis, and defects in FeS cluster assembly can indirectly impair molybdenum cofactor function. The sulfurtransferase step itself is downstream of the core MOCS1, MOCS2, and GEPH/MOCOS functions in humans.
Regulation and pathway context
In simple terms: The activity is controlled by the availability of substrates and the upstream pathway.
The sulfurtransferase step depends on the availability of Mo-molybdopterin, L-cysteine, and reducing equivalents, and it is therefore regulated by the upstream cofactor biosynthesis machinery. In humans, mutations in MOCS1, MOCS2, or GPHN can disrupt the pathway before sulfurylation, while MOCOS defects specifically impair the sulfurtransferase step. High molybdenum concentrations can restore xanthine dehydrogenase activity in some bacterial mutants, indicating that metal availability influences cofactor maturation.
Physiological consequences of sulfurylation
In simple terms: Once sulfurylated, the cofactor can power enzymes that detoxify sulfite and break down purines.
Thio-Mo-molybdopterin is required for sulfite oxidase, which converts sulfite to sulfate, and for xanthine dehydrogenase, which participates in purine catabolism. Loss of sulfurtransferase activity therefore leads to sulfite accumulation and xanthine stones, as seen in molybdenum cofactor deficiency and hereditary xanthinuria. The severity of the phenotype depends on the residual activity of the pathway, with some MOCS2 variants causing milder disease.
Key Genes Involved in GO:0008265 molybdenum cofactor sulfurtransferase activity
The following genes and proteins are directly or indirectly involved in molybdenum cofactor sulfurtransferase activity and its pathway context.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MOCOS | Human molybdenum cofactor sulfurase; performs the sulfurtransferase step | Mutations cause molybdenum cofactor deficiency; target for functional studies |
| MOCS1 | Involved in the first steps of molybdopterin biosynthesis | Mutations cause cofactor deficiency; used to dissect pathway order |
| MOCS2 | Molybdopterin synthase subunit; builds the cofactor backbone | Variants including Roma founder mutation cause mild disease |
| GPHN | Gephyrin; involved in molybdopterin biosynthesis and synaptic clustering | Mutations cause cofactor deficiency; links to neurobiology |
| MOCS3 | Molybdopterin synthase sulfurylase in some organisms | Model for sulfur transfer mechanisms |
| SUOX | Sulfite oxidase; uses thio-Mo-molybdopterin | Readout of sulfurtransferase activity; accumulates sulfite when defective |
| XDH | Xanthine dehydrogenase; uses thio-Mo-molybdopterin | Readout of cofactor activity; xanthinuria model |
| AOX1 | Aldehyde oxidase; molybdoenzyme | Potential downstream reporter of cofactor status |
| NFS1 | Cysteine desulfurase; provides sulfur for FeS clusters | Links sulfur metabolism to cofactor maturation |
| ISCU | FeS cluster scaffold | Affects molybdoenzyme maturation in bacteria |
| SUFD | FeS cluster assembly | Bacterial model for cofactor maturation |
| MOEA | Bacterial molybdenum cofactor biosynthesis | Mutants show restored activity with high molybdenum |
| MOCS1A | Bacterial homolog of MOCS1 | Comparative studies of cofactor biosynthesis |
| MOCS2A | Small subunit of molybdopterin synthase | Structural and functional studies |
| MOCS2B | Large subunit of molybdopterin synthase | Catalytic core of cofactor backbone synthesis |
| GEPH | Gephyrin splice variants | Alternative splicing affects cofactor function |
| MOCOS2 | Paralog or alternative name in some databases | Annotation caution; verify in primary literature |
How Is molybdenum cofactor sulfurtransferase activity Regulated?
The sulfurtransferase step is regulated by the availability of its substrates (Mo-molybdopterin, L-cysteine, and reducing equivalents) and by the upstream cofactor biosynthesis machinery. In humans, the pathway is controlled by the expression and stability of MOCS1, MOCS2, GPHN, and MOCOS, and mutations in any of these genes can reduce sulfurtransferase activity. Bacterial studies show that molybdenum availability can influence cofactor maturation, as high molybdenum concentrations restore xanthine dehydrogenase activity in moeA mutants. There is no evidence in the provided literature for direct regulation by mTOR or the integrated stress response, so those mechanisms should not be assumed.
molybdenum cofactor sulfurtransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MOCOS | Molybdenum cofactor deficiency | Knockout or point-mutation cell lines; sulfite oxidase activity assay |
| MOCS2 | Mild cofactor deficiency (Roma founder variant) | Knock-in of the variant; patient-derived cells |
| MOCS1 | Severe cofactor deficiency | Knockout models; metabolic rescue studies |
| GPHN | Cofactor deficiency with neurological features | Neuronal knockout models; gephyrin clustering assays |
| XDH | Hereditary xanthinuria | Goat or cell models; xanthine dehydrogenase activity |
Molybdenum cofactor deficiency
Molybdenum cofactor deficiency is a severe autosomal recessive disorder caused by mutations in MOCS1, MOCS2, GPHN, or MOCOS, leading to loss of sulfurtransferase activity and inactivation of sulfite oxidase and xanthine dehydrogenase. Affected infants typically present with intractable seizures, feeding difficulties, brain atrophy, and developmental regression, often leading to early death. The accumulation of sulfite and other toxic metabolites is thought to drive the neurological damage.
Mild and atypical forms
Not all cofactor deficiency is equally severe. A prevalent MOCS2 variant in the Roma population has been associated with a novel mild form of molybdenum cofactor deficiency, suggesting that residual sulfurtransferase activity can modify the phenotype. This highlights the importance of functional assays to distinguish pathogenic from hypomorphic variants.
Hereditary xanthinuria
Defects in the molybdenum cofactor pathway can also present as hereditary xanthinuria, as documented in a goat model. Because xanthine dehydrogenase requires thio-Mo-molybdopterin, loss of sulfurtransferase activity leads to xanthine accumulation and stone formation. This condition provides a comparative window into the biochemical consequences of cofactor inactivation.
From molybdenum cofactor sulfurtransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of MOCOS abolish sulfurtransferase activity? | MOCOS knockout cell line |
| Can a patient variant be rescued by wild-type MOCOS? | Point-mutation knock-in with rescue overexpression |
| What is the effect of a mild MOCS2 variant on cofactor function? | Knock-in of the Roma variant in a human cell line |
| Can tagged MOCOS be used to track localization? | Tagged knock-in (e.g., GFP or HA) |
| Does overexpression of MOCOS increase sulfite oxidase activity? | Overexpression cell model |
| How does molybdenum availability affect cofactor maturation? | Bacterial moeA mutant with high molybdenum |
How to Study the molybdenum cofactor sulfurtransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Sulfite oxidase activity assay | Functional sulfurylation of cofactor | Diagnosis and model validation |
| Xanthine dehydrogenase activity assay | Cofactor-dependent purine catabolism | Bacterial and animal models |
| CRISPR knockout | Loss-of-function phenotype | Testing gene essentiality |
| Point-mutation knock-in | Variant pathogenicity | Patient variant modeling |
| Metabolite profiling (LC-MS) | Sulfite, xanthine, and related metabolites | Disease biomarker discovery |
| Tagged knock-in | Protein localization and interactions | Cell biology of MOCOS |
| Overexpression | Gain-of-function and rescue | Testing sufficiency of sulfurtransferase |
| Sequencing (NGS/Sanger) | Mutation identification | Clinical genetics of cofactor deficiency |
Biochemical activity assays
Sulfurtransferase activity can be inferred by measuring the activity of downstream molybdoenzymes such as sulfite oxidase and xanthine dehydrogenase. In bacterial systems, xanthine dehydrogenase activity can be restored by high molybdenum in moeA mutants, providing a sensitive readout. In mammalian cells, sulfite oxidase activity is a key marker of cofactor sulfurylation.
Genetic and genomic approaches
CRISPR knockout and knock-in models are used to test the function of MOCOS, MOCS1, MOCS2, and GPHN. Sanger or next-generation sequencing of patient cohorts has identified mutations in these genes, including the Roma MOCS2 variant. Comparative genomics of bacterial and eukaryotic pathways helps annotate the sulfurtransferase step.
Metabolite profiling
Measurement of sulfite, xanthine, and related metabolites in urine or plasma can reveal loss of sulfurtransferase activity. In goats with hereditary xanthinuria, xanthine stones and elevated xanthine are diagnostic. In human cofactor deficiency, sulfite accumulation and altered purine metabolites are characteristic.
Protein interaction and localization
Tagged knock-in approaches can be used to study the localization and interactions of MOCOS and other pathway proteins. Co-immunoprecipitation and mass spectrometry can identify partners in the cofactor biosynthesis machinery. These methods help place the sulfurtransferase step within the broader cellular network.
How CRISPR Can Be Used to Study GO:0008265 molybdenum cofactor sulfurtransferase activity
Knockout
CRISPR knockout of MOCOS or other pathway genes can abolish sulfurtransferase activity and produce a measurable loss of sulfite oxidase and xanthine dehydrogenase function. These models are useful for confirming the role of a candidate gene in cofactor maturation and for testing rescue strategies.
Point Mutation
Point-mutation knock-in can recreate patient-specific variants, such as the Roma MOCS2 allele, to assess residual activity and genotype-phenotype correlations. This approach is essential for classifying variants of uncertain significance in the cofactor pathway.
Knock-in
Knock-in of tagged or reporter alleles allows tracking of MOCOS expression, localization, and interactions in live cells. This can reveal how the sulfurtransferase step is integrated with the rest of the cofactor biosynthesis machinery.
Overexpression
Overexpression of MOCOS or upstream pathway genes can test whether increased sulfurtransferase activity is sufficient to enhance molybdoenzyme function. Such models are also useful for producing recombinant protein for biochemical studies.
How EDITGENE Supports molybdenum cofactor sulfurtransferase activity Research
Researchers studying molybdenum cofactor sulfurtransferase activity-related genes often need to determine whether a candidate gene is causally involved in cofactor maturation or whether a variant is pathogenic. This requires precise genetic models that can isolate the sulfurtransferase step from the rest of the pathway.
Contact EDITGENE today to design your custom CRISPR model for molybdenum cofactor sulfurtransferase activity research.
Frequently Asked Questions About molybdenum cofactor sulfurtransferase activity
What is molybdenum cofactor sulfurtransferase activity?
It is the enzymatic activity (GO:0008265) that transfers sulfur from L-cysteine to Mo-molybdopterin, forming active thio-Mo-molybdopterin.
What genes are involved in molybdenum cofactor sulfurtransferase activity?
The main human gene is MOCOS, with upstream roles for MOCS1, MOCS2, and GPHN.
What diseases are associated with defects in this activity?
Molybdenum cofactor deficiency and hereditary xanthinuria are the main associated conditions.
What is the reaction catalyzed by GO:0008265?
AH2 + L-cysteine + Mo-molybdopterin = A + H2O + L-alanine + thio-Mo-molybdopterin.
Why is sulfurylation of the molybdenum cofactor important?
Without sulfurylation, molybdoenzymes such as sulfite oxidase and xanthine dehydrogenase cannot function.
How is molybdenum cofactor sulfurtransferase activity studied?
It is studied using enzyme activity assays, CRISPR models, and metabolite profiling.
What are the symptoms of molybdenum cofactor deficiency?
Symptoms include neonatal seizures, brain atrophy, developmental regression, and early death.
Can mild forms of cofactor deficiency occur?
Yes, a prevalent MOCS2 variant in the Roma population is associated with a mild form.
What is the role of MOCOS in the pathway?
MOCOS encodes the sulfurase that performs the final sulfur transfer step on the cofactor.
How can CRISPR help study this pathway?
CRISPR knockout, knock-in, and point-mutation models allow precise testing of gene function and variant pathogenicity.
Conclusion
GO:0008265, molybdenum cofactor sulfurtransferase activity, is a critical molecular function that activates the molybdenum cofactor by transferring sulfur from L-cysteine to Mo-molybdopterin. Its importance is underscored by molybdenum cofactor deficiency, a severe inherited disease caused by defects in the pathway, and by milder phenotypes associated with hypomorphic variants. Continued research using CRISPR models and biochemical assays will clarify how this activity is regulated and how it can be targeted therapeutically.
References
- 1. Adam MP et al.. 1993. Molybdenum Cofactor Deficiency.. PMID: 34870926
- 2. Mendel RR. 2009. Cell biology of molybdenum.. Biofactors 35(5):429-34 PMID: 19623604
- 3. Yokoyama K et al.. 2015. The role of FeS clusters for molybdenum cofactor biosynthesis and molybdoenzymes in bacteria.. Biochim Biophys Acta 1853(6):1335-49 PMID: 25268953
- 4. Reiss J et al.. 2003. Mutations in the molybdenum cofactor biosynthetic genes MOCS1, MOCS2, and GEPH.. Hum Mutat 21(6):569-76 PMID: 12754701
- 5. Reiss J et al.. 2011. Molybdenum cofactor deficiency: Mutations in GPHN, MOCS1, and MOCS2.. Hum Mutat 32(1):10-8 PMID: 21031595
- 6. Leimkühler S et al.. 1999. Activity of the molybdopterin-containing xanthine dehydrogenase of Rhodobacter capsulatus can be restored by high molybdenum concentrations in a moeA mutant defective in molybdenum cofactor biosynthesis.. J Bacteriol 181(19):5930-9 PMID: 10498704
- 7. Vail KJ et al.. 2019. Hereditary xanthinuria in a goat.. J Vet Intern Med 33(2):1009-1014 PMID: 30758870
- 8. Cho SK et al.. 2025. A prevalent MOCS2 variant in the Roma population is associated with a novel mild form of molybdenum cofactor deficiency.. Eur J Pediatr 184(8):499 PMID: 40707723
